Recruiting PHASE3 INTERVENTIONAL 2-arm NCT07063095

A Combination Therapy With Ceftazidime and Fosfomycin Will be Compared to Ceftazidime Alone in Hospitalized Adult Patients With Suspected Severe Gram-negative Bacterial Infections (CAVIFOS)

Ceftazidime Plus Fosfomycin Versus Ceftazidime Alone for Severe Gram-negative Infections: a Triple-blind, Placebo-controlled Point-of-care Randomized Clinical Trial

Sponsor: Angela HUTTNER

Conditions Gram Negative Infections Sepsis and Septic Shock

Interventions Ceftazidime± avibactam with fosfomycin Ceftazidime± avibactam with placebo

Updated 3 times since 2025 Last updated: Sep 25, 2025 Started: Aug 25, 2025 Primary completion: Dec 31, 2026 Completion: Dec 31, 2026

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE3 trial investigates Gram Negative Infections and Sepsis and Septic Shock and is currently actively recruiting participants. Angela HUTTNER leads this study, which shows 3 recorded versions since 2025 — indicating limited longitudinal coverage. Longitudinal tracking of infectious disease trials helps identify durability of treatment effects.

Status Flow

Change History

3 versions recorded

Oct 2025 — Present [monthly]

Recruiting PHASE3
Sep 2025 — Oct 2025 [monthly]

Recruiting PHASE3

Status: Not Yet Recruiting → Recruiting
Aug 2025 — Sep 2025 [monthly]

Not Yet Recruiting PHASE3

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Angela HUTTNER
Joint Programming Initiative on Antimicrobial Resistance (JPIAMR)
Swiss National Science Foundation

Data source: University of Geneva, Switzerland

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Geneva, Switzerland